bevacizumab 400 mg-Bevacizumab Biosimilar for Advanced Cancer treatment-bevacizumab Dose,uses & side effects

Cizumab (Bevacizumab Biosimilar Injection) is a DCGI-approved biosimilar of Bevacizumab, used in the treatment of various cancers, including colorectal and rectal cancer, ovarian cancer, kidney cancer, cervical cancer, lung cancer, and certain brain tumors. It works by inhibiting vascular endothelial growth factor (VEGF), helping to reduce the formation of new blood vessels that supply tumors, thereby slowing cancer growth and spread. Bevacizumab is administered under medical supervision according to the prescribed dose and treatment regimen. Common side effects may include hypertension, fatigue, bleeding, and proteinuria. Patients should consult their oncologist regarding dosage, precautions, monitoring, and potential treatment benefits.